BBOT — Q2 2026 Financial Report Analysis

BridgeBio Oncology Therapeutics (BBOT), a drug developer with no products on the market yet, lost $56.5 million in the second quarter of 2026, nearly double the $28.4 million it lost a year earlier. The cause was spending on its three cancer drugs in clinical trials: research and development (R&D) costs rose 79% to $49.2 million. Its cash and short-term investments stood at $344.1 million at June 30, down from $425.5 million at the end of 2025. Management still expects that to fund the company "into 2028." BBOT had no revenue in the quarter or a year ago, so this report focuses on spending, cash and the trial pipeline.

At a glance

• $49.2 million R&D in the quarter (+79% YoY): $17.5 million of the $21.8 million increase came from clinical trial and drug-manufacturing costs across all three programs. Most of the extra spending is going into trials.
• $344.1 million cash, runway "into 2028": the company spent $80.3 million of cash on operations in the first half, about $40 million a quarter. That is roughly eight quarters of cash at that pace, but quarterly spending is still rising.
• Loss per share $0.71 vs $0.57 (+24%) while the net loss rose 99%: the per-share figure grew much more slowly only because there are about 60% more shares now, mostly new stock issued when the company listed in August 2025.

What BBOT is and what it's testing

KRAS is a gene that normally works like an on/off switch for cell growth. Certain mutations jam it in the "on" position, and KRAS is the most commonly mutated cancer-driving gene in human tumors. BBOT's three drugs all attack that pathway. All three are taken as pills and are in Phase 1 trials (early studies that test safety, dose and first signs of tumor shrinkage):

BBOT's plan is to combine its own drugs, so it can block both of the growth signals KRAS sends (the MAPK and PI3Kα pathways) without licensing a partner's drug. It is a separate public company from BridgeBio Pharma (BBIO). It was carved out of BridgeBio Pharma, which still provides some services under a transition agreement, and listed on Nasdaq in August 2025 by merging with a special-purpose acquisition company (SPAC), Helix Acquisition Corp. II.

Second-quarter results

Revenue and operating margin don't apply because BBOT has no approved product.

R&D. Of the $21.8 million increase in R&D, $17.5 million was "trials and consumables": higher clinical trial and manufacturing costs for all three drugs. Another $3.6 million came from hiring more staff and $0.6 million from consultant and professional fees. Spending is also speeding up within the year. Total operating expenses were $46.2 million in Q1 2026 (the $106.4 million six-month total minus Q2's $60.2 million) and $60.2 million in Q2.

General and administrative (G&A) costs rose from $2.7 million to $11.0 million. These are the overhead costs of running the company outside the lab. A year ago BBOT was a private company that got many services from BridgeBio Pharma. Now it pays for its own staff and the legal and audit costs of being public. G&A also included $3.0 million of stock-based pay and accrued severance for former executives (see below).

Six months. First-half net loss was $98.6 million, compared with $50.5 million in the first half of 2025. R&D was $89.0 million, up 85%.

What the headline numbers hide

• Some Q2 overhead won't repeat. G&A included $3.0 million of stock-based compensation from changed equity awards and accrued severance for former executives. That includes a $2.0 million non-cash charge from extending the time former executives have to exercise their stock options. Without these items, G&A would have been about $8 million. That is still about three times the year-ago level, because the cost of operating as a standalone public company is permanent.
• Cash burn ran below the net loss, partly because bills went unpaid until later. First-half operating cash outflow was $80.3 million against a $98.6 million net loss. $11.8 million of the gap is non-cash, mostly $11.1 million of stock-based pay (up from $1.5 million a year earlier). The other $6.5 million came from owing suppliers more: accrued R&D costs rose $10.9 million and accounts payable rose $5.4 million. Those amounts will be paid in cash later, so the underlying burn is closer to $87 million for the half than $80 million.
• Runway math. At the first half's roughly $40 million of cash a quarter, $344.1 million would last about eight to nine quarters, into the second half of 2028. Q2 operating expenses were about 30% above Q1's, though, and the 10-Q warns that operating losses are "expected to increase." That makes "into 2028" a reasonable statement but not a generous one. The 10-Q also says current cash "will not be sufficient to fund all of our product candidates through regulatory approval." Expect another share sale or a partnership before any drug reaches market.
• Dilution has already happened, and more may follow. The weighted share count rose from 50.2 million to 80.1 million, mainly from the August 2025 SPAC merger and a $260.9 million private share sale to investors (a PIPE) that closed alongside it. As a result, the loss per share rose only 24% even though the net loss nearly doubled. 80,174,267 shares were outstanding on August 6, 2026.
• Interest income is cushioning the loss. Interest income of $3.6 million (up from $1.7 million) on the cash pile offset about 6% of operating costs. That cushion shrinks as the cash is spent.
• A data-entry error in the filing. Both the 10-Q and the earnings release print the per-share loss as "$(705.20)" and the weighted share count as "80,054," apparently in thousands. That is a units error: $56.5 million divided by 80.1 million shares is a loss of $0.71 per share, and the cover page reports about 80.2 million shares outstanding. We use $0.71.

Takeaway: BBOT is spending faster, not slower. Quarterly operating costs doubled year over year and rose about 30% from Q1. The $344 million cash pile has to last through several data readouts. The September decision to focus spending on fewer trials is what makes the "into 2028" runway believable, so how fast costs grow over the next two quarters matters as much as the trial results.

Clinical update since the quarter ended

On September 8, 2026, BBOT released new BBO-8520 data (data cutoff June 1, 2026). It also said it would focus its spending on fewer trials:

• BBO-8520 plus pembrolizumab, in lung cancer patients whose disease already progressed on an older G12C drug: the objective response rate (ORR) was 75% at the 500 mg once-daily dose and 53% across all doses (N=17). ORR is the share of patients whose tumors shrank by a set amount. The company described side effects as mainly gastrointestinal, with "a favorable liver safety profile."
• BBO-8520 alone, in previously treated lung cancer patients who hadn't received a G12C drug: ORR was 63% (26 of 41) and the disease control rate was 100% (41 of 41; tumors shrank or stopped growing). 21 of 28 patients followed for at least six months were still on treatment, with no grade 3 (severe) liver enzyme elevations.
• Focus: BBOT said it is concentrating capital on (1) BBO-8520 plus pembrolizumab in lung cancer patients who already received a G12C drug and (2) combinations of BBO-11818 and BBO-10203 with each other and with standard treatments in KRAS-mutant cancers. BBO-8520 alone in patients new to G12C drugs is not on that priority list, despite the 63% response rate. The company argues that as current G12C drugs move into first-line treatment, more patients will relapse on them, and no targeted therapy is approved for that group. It estimates about 21,000 U.S. lung cancer patients will be diagnosed with the KRAS G12C mutation in 2026.

These are small, early, single-arm results without a comparison group. Response rates in groups of 17 to 41 patients often move a lot as more patients enroll.

Outlook

Management's stated catalysts over the next 12 months:

• Q4 2026: BBO-11818 and BBO-10203 single-drug data update. This is the next test of whether the pan-KRAS and PI3Kα programs work in patients.
• Mid-2027: more data on BBO-8520 plus pembrolizumab in lung cancer patients who already received a G12C drug.
• Mid-2027: first data from the BBO-11818 and BBO-10203 combination trials in colorectal and pancreatic cancer.

Our view: in Q4 2026 and early 2027, watch whether operating expenses level off near Q2's $60 million a quarter now that the trial list is narrower. If they keep rising at the Q1-to-Q2 rate, the cash may not last until the mid-2027 data arrive without new funding. The Q4 2026 data on BBO-11818 and BBO-10203 alone matter more for the stock than the next quarterly report, because the company's two prioritized combination strategies both depend on those drugs.